Boyi Yuan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Boyi Yuan has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Baolei Xu
National Clinical Research Center for Geriatric Diseases, Xuanwu Hospital, Capital Medical University, Beijing, China
1 shared publicationChao Wu
Department of Neurology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
1 shared publication- Chun Liu
Department of Neurology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
1 shared publication - Dan Miao
Department of Neurology, Qingdao Hiser Hospital, Qingdao University, Qingdao, Shandong, China
1 shared publication - Guang-Zhi Liu
Department of Neurology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
1 shared publication - Guobin Yuan
Department of Neurology, The Second Qilu Hospital of Shandong University, Jinan, Shandong, China
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 1 January 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (1) , 50-62
Tenecteplase for Acute Ischemic Stroke at 4.5 to 24 Hours: A Meta-Analysis of Randomized Controlled Trials
BACKGROUND: Whether TNK (tenecteplase) benefits patients with acute ischemic stroke treated within 4.5 to 24 hours remains uncertain, and no previous meta-analysis has differentiated between clinical settings where endovascular thrombectomy (EVT) is unavailable or permitted, leading to pooled distinct clinical contexts and obscuring a clear estimation of TNK’s net effect. METHODS: We searched for randomized controlled trials comparing intravenous TNK of 0.25 mg/kg with standard care or placebo in adults within 4.5 to 24 hours after acute ischemic stroke onset. The primary outcome was excellent functional outcome (modified Rankin Scale score, 0–1) at 90 days, with additional efficacy and safety end points. A random-effects meta-analysis was performed both overall and within predefined subgroups, stratified by whether EVT was permitted in individual studies (non-EVT versus EVT-permitted). RESULTS: Four multicenter randomized controlled trials enrolling 1278 patients were included. TNK significantly increased excellent functional outcome (odds ratio [OR], 1.34 [95% CI, 1.06–1.71]; P =0.02) at 90 days and recanalization (OR, 3.30 [95% CI, 1.59–6.84]; P =0.001) compared with the control group, whereas good functional outcome (modified Rankin Scale score, 0–2), reperfusion, and early neurological improvement did not differ significantly. Subgroup analyses of 596 patients in the non-EVT subgroup showed that TNK significantly improved excellent functional outcome (OR, 1.46 [95% CI, 1.02–2.08]; P =0.04), good functional outcome (OR, 1.50 [95% CI, 1.07–2.09]; P =0.02), recanalization (OR, 6.17 [95% CI, 3.36–11.33]; P P P =0.003). No significant differences were observed between TNK and control in the risks of symptomatic intracerebral hemorrhage or 90-day mortality, either in the overall or subgroup analyses. CONCLUSIONS: TNK improves excellent functional outcomes and recanalization in patients with acute ischemic stroke treated within 4.5 to 24 hours, without increasing the risks of symptomatic intracerebral hemorrhage or mortality. Notably, extended-window TNK provides greater additional benefits when EVT is inaccessible, establishing its role as an alternative reperfusion strategy in resource-limited settings.
- 1 January 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (1) , 50-62
Top Cited PapersOpen AccessTenecteplase for Acute Ischemic Stroke at 4.5 to 24 Hours: A Meta-Analysis of Randomized Controlled Trials
BACKGROUND: Whether TNK (tenecteplase) benefits patients with acute ischemic stroke treated within 4.5 to 24 hours remains uncertain, and no previous meta-analysis has differentiated between clinical settings where endovascular thrombectomy (EVT) is unavailable or permitted, leading to pooled distinct clinical contexts and obscuring a clear estimation of TNK’s net effect. METHODS: We searched for randomized controlled trials comparing intravenous TNK of 0.25 mg/kg with standard care or placebo in adults within 4.5 to 24 hours after acute ischemic stroke onset. The primary outcome was excellent functional outcome (modified Rankin Scale score, 0–1) at 90 days, with additional efficacy and safety end points. A random-effects meta-analysis was performed both overall and within predefined subgroups, stratified by whether EVT was permitted in individual studies (non-EVT versus EVT-permitted). RESULTS: Four multicenter randomized controlled trials enrolling 1278 patients were included. TNK significantly increased excellent functional outcome (odds ratio [OR], 1.34 [95% CI, 1.06–1.71]; P =0.02) at 90 days and recanalization (OR, 3.30 [95% CI, 1.59–6.84]; P =0.001) compared with the control group, whereas good functional outcome (modified Rankin Scale score, 0–2), reperfusion, and early neurological improvement did not differ significantly. Subgroup analyses of 596 patients in the non-EVT subgroup showed that TNK significantly improved excellent functional outcome (OR, 1.46 [95% CI, 1.02–2.08]; P =0.04), good functional outcome (OR, 1.50 [95% CI, 1.07–2.09]; P =0.02), recanalization (OR, 6.17 [95% CI, 3.36–11.33]; P P P =0.003). No significant differences were observed between TNK and control in the risks of symptomatic intracerebral hemorrhage or 90-day mortality, either in the overall or subgroup analyses. CONCLUSIONS: TNK improves excellent functional outcomes and recanalization in patients with acute ischemic stroke treated within 4.5 to 24 hours, without increasing the risks of symptomatic intracerebral hemorrhage or mortality. Notably, extended-window TNK provides greater additional benefits when EVT is inaccessible, establishing its role as an alternative reperfusion strategy in resource-limited settings.
- Open Access
- 17 November 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (1) , 286-302
Global, regional, and national burden of brain and other central nervous system cancers from 1990 to 2021, and projections to 2035: a systematic analysis for the global burden of disease study 2021
Background: The burden of primary brain and other central nervous system (CNS) cancers, collectively termed CNS cancers, has undergone significant changes in recent decades. This study aimed to estimate the burden, trends, and inequalities at the global, regional, and national levels from 1990 to 2021, as well as projections to 2035. Methods: We used 2021 Global Burden of Disease (GBD) Study data and methodologies to describe changes in the burden of CNS cancers from 1990 to 2021, including prevalence, incidence, mortality, and disability-adjusted life years (DALYs). Furthermore, the autoregressive integrated moving average model was used to forecast the future CNS cancer burden until 2035. Finally, we conducted decomposition analysis to identify the key drivers of variation in CNS cancer burden. Frontier analysis was used to visually illustrate the potential for burden reduction in each country or region based on their development levels. Results: From 1990 to 2021, global cases of CNS cancers have increased in prevalence and incidence by 124.50% and 106.53%, respectively, with corresponding increases in related age-standardized rates (ASRs). A similar increase in the number was also observed in CNS cancer-related mortality and DALYs, accompanied by a decline in the ASRs of DALYs and a stable state in the ASRs of mortality. Sex and age data from the GBD 2021 demonstrated an exclusively older male predominance in CNS cancer-related ASRs of prevalence, incidence, mortality, and DALYs. In 2021, regions with a high Socio-Demographic Index (SDI) had the highest ASRs of prevalence, incidence, mortality, and DALYs. By 2035, the estimated global number of prevalent cases, incident cases, deaths, and DALYs is projected to be 1.22 million, 0.43 million, 0.31 million, and 10.27 million, with an increase of 24%, 19%, 19%, and 15% from 2021 to 2035, respectively, though the ASRs of incidence and DALYs decreased to some extent. Decomposition analysis showed the major contributory roles of population growth and aging on the incidence, mortality, and DALYs, although epidemiological changes also contributed to the prevalence to some extent. Frontier analysis of 204 countries and regions indicated that a higher SDI was associated with higher CNS cancer-related ASRs of prevalence, incidence, mortality, and DALYs and that countries or regions with higher SDI levels tended to have greater potential for improvement. Conclusions: Life expectancy for individuals with CNS cancers has increased since the 1990s, coinciding with a substantial reduction in the DALY rate and a stable CNS cancer-related mortality rate. However, mortality and DALYs related to CNS cancers have been particularly high in men across all age groups, those residing in higher SDI regions, and older adults. Considering the continuous increase in the CNS cancer burden by 2035, efficacious management of CNS cancers continues to pose a substantial challenge, highlighting the need for more regionally tailored strategies and guidelines on the sex-specific treatment protocols for older males to alleviate the disease burden, which is largely driven by aging and population growth in different SDI regions.
- 17 November 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (1) , 286-302
Open AccessGlobal, regional, and national burden of brain and other central nervous system cancers from 1990 to 2021, and projections to 2035: a systematic analysis for the global burden of disease study 2021
Background: The burden of primary brain and other central nervous system (CNS) cancers, collectively termed CNS cancers, has undergone significant changes in recent decades. This study aimed to estimate the burden, trends, and inequalities at the global, regional, and national levels from 1990 to 2021, as well as projections to 2035. Methods: We used 2021 Global Burden of Disease (GBD) Study data and methodologies to describe changes in the burden of CNS cancers from 1990 to 2021, including prevalence, incidence, mortality, and disability-adjusted life years (DALYs). Furthermore, the autoregressive integrated moving average model was used to forecast the future CNS cancer burden until 2035. Finally, we conducted decomposition analysis to identify the key drivers of variation in CNS cancer burden. Frontier analysis was used to visually illustrate the potential for burden reduction in each country or region based on their development levels. Results: From 1990 to 2021, global cases of CNS cancers have increased in prevalence and incidence by 124.50% and 106.53%, respectively, with corresponding increases in related age-standardized rates (ASRs). A similar increase in the number was also observed in CNS cancer-related mortality and DALYs, accompanied by a decline in the ASRs of DALYs and a stable state in the ASRs of mortality. Sex and age data from the GBD 2021 demonstrated an exclusively older male predominance in CNS cancer-related ASRs of prevalence, incidence, mortality, and DALYs. In 2021, regions with a high Socio-Demographic Index (SDI) had the highest ASRs of prevalence, incidence, mortality, and DALYs. By 2035, the estimated global number of prevalent cases, incident cases, deaths, and DALYs is projected to be 1.22 million, 0.43 million, 0.31 million, and 10.27 million, with an increase of 24%, 19%, 19%, and 15% from 2021 to 2035, respectively, though the ASRs of incidence and DALYs decreased to some extent. Decomposition analysis showed the major contributory roles of population growth and aging on the incidence, mortality, and DALYs, although epidemiological changes also contributed to the prevalence to some extent. Frontier analysis of 204 countries and regions indicated that a higher SDI was associated with higher CNS cancer-related ASRs of prevalence, incidence, mortality, and DALYs and that countries or regions with higher SDI levels tended to have greater potential for improvement. Conclusions: Life expectancy for individuals with CNS cancers has increased since the 1990s, coinciding with a substantial reduction in the DALY rate and a stable CNS cancer-related mortality rate. However, mortality and DALYs related to CNS cancers have been particularly high in men across all age groups, those residing in higher SDI regions, and older adults. Considering the continuous increase in the CNS cancer burden by 2035, efficacious management of CNS cancers continues to pose a substantial challenge, highlighting the need for more regionally tailored strategies and guidelines on the sex-specific treatment protocols for older males to alleviate the disease burden, which is largely driven by aging and population growth in different SDI regions.